WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018055573) TREATING CLUSTER HEADACHE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/055573 International Application No.: PCT/IB2017/055776
Publication Date: 29.03.2018 International Filing Date: 22.09.2017
IPC:
A61K 39/395 (2006.01) ,A61P 25/06 (2006.01)
Applicants: TEVA PHARMACEUTICALS INTERNATIONAL GMBH[CH/CH]; Rapperswil-Jona Schlusselstrasse 12 8645 Jona, CH
Inventors: BIGAL, Marcelo; US
AYCARDI, Ernesto; US
COHENBARAK, Orit; IL
Agent: CONROY, John F.; DE
Priority Data:
62/399,15623.09.2016US
Title (EN) TREATING CLUSTER HEADACHE
(FR) TRAITEMENT DE L'ALGIE VASCULAIRE DE LA FACE
Abstract:
(EN) Disclosed herein are methods of treating or reducing incidence of a cluster headache, e.g., chronic cluster headache and episodic cluster headache, and/or at least one secondary symptom associated with a cluster headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
(FR) L'invention concerne des méthodes de traitement ou de réduction de l'incidence d'une algie vasculaire de la face (céphalée en grappe), par exemple de céphalée en grappe chronique, et de céphalée en grappe épisodique et/ou d'au moins un symptôme secondaire associé à une algie vasculaire de la face chez un sujet consistant à administrer au sujet un anticorps monoclonal qui module la voie du peptide relié au gène de la calcitonine (PRGC). L'invention concerne également des compositions destinées à être utilisées dans les méthodes de l'invention. L'invention concerne en outre l'anticorps antagoniste G1 et des anticorps dérivés de G1 dirigés contre le PRGC.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)